A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

What Was Tested

In this phase 3 trial, researchers set out to test Tirzepatide and Cagrilintide.

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight.

CagriSema is not yet being prescribed by doctors.

It had two arms (groups): one (experimental) and one (active comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 809 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female. Age 18 years or above at the time of signing the informed consent. Body mass index (BMI) of ≥ 30.0 kilogram per square meter (kg/m\^2).

The full record lists 3 inclusion and 2 exclusion criteria; among the exclusions: history of type 1 or type 2 diabetes mellitus.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Being open-label, the Tirzepatide study did not mask who received what.

It started in 2023-11-27 with completion listed for 2025-12-08.

It ran at 46 sites in United States (46).

Its stated primary purpose is treatment.

What Was Measured

It also tracked 14 secondary outcomes, for example Change in waist circumference, Change in systolic blood pressure (SBP), Change in diastolic blood pressure (DBP), Relative change in lipids: Total cholesterol, Relative change in lipids: High-density lipoprotein (HDL) cholesterol and Relative change in lipids: Non-HDL cholesterol.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Tirzepatide and Cagrilintide in 809 people.

With 809 participants it is a large trial for this field.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Cagrilintide compound page, all human trials.